RxDoctor Payments Data

David Witt, MD

Family Medicine · Longview, TXNPI 1538136528

Payments from drug & device makers

$9,109in general payments, 2019–2025

Across 653 payments — averaging $13.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Amgen$933
  • GSK$830
  • AbbVie$776
  • Pfizer$734
  • AstraZeneca$617
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$9,103100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,109 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$320,894
Medicare patients
825
Services billed
16,403

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban94$69,144
JardianceEmpagliflozin35$34,975
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$23,471
OzempicSemaglutide17$16,484
XareltoRivaroxaban24$14,270
MounjaroTirzepatide14$13,717
Fluticasone-SalmeterolFluticasone Propion/Salmeterol34$8,065
SymbicortBudesonide/Formoterol Fumarate18$7,422
Tresiba Flextouch U-100Insulin Degludec11$7,299
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$3,729
Metoprolol Succinate226$3,053
Rosuvastatin Calcium353$2,762
Pantoprazole Sodium212$2,659
Wixela InhubFluticasone Propion/Salmeterol20$2,633
Levothyroxine Sodium237$2,625

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$734$69,14494 claims
Boehringer IngelheimJardiance$408$34,97535 claims
GSKTrelegy Ellipta$830$23,47119 claims
Novo NordiskOzempic$1,156$16,48417 claims
Johnson & JohnsonXarelto$262$14,27024 claims
Lilly USA, LLCMounjaro$613$13,71714 claims
AstraZenecaSymbicort$617$7,42218 claims
Almatica Pharma LLCSertraline Hcl$18$1,12581 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Longview

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →